Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NMRA
Strong SellSinkerNeumora Therapeutics, Inc. · Healthcare · United States · $261M · Avg Vol: $796K/d
COMPANY DESCRIPTION
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines for neurodegenerative and neuropsychiatric diseases. The company employs a data-driven, genomics-informed approach to identify disease mechanisms and target specific patient populations, aiming to improve clinical success rates in challenging therapeutic areas. Neumora is advancing a pipeline of novel small molecules addressing significant unmet needs in central nervous system disorders.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 1.3M | — |
| EPS | -1.56 | -0.86 | -3.63 | -1.53 | -1.45 | — | -1.23 | -0.87 | -0.67 | — |
| Shares | 151.9M | 151.9M | 158.8M | 161.7M | 174.3M | +14.7% | 187.9M | — | — | — |
| Debt | 2.1M | 8.4M | 5.2M | 1.9M | 55.0M | 127.5% | 53.3M | — | — | — |
| Equity | -325.2M | -446.9M | 469.1M | 287.1M | 103.9M | -52.9% | — | — | — | — |
| Op CF | -75.4M | -114.9M | -163.3M | -182.9M | -206.4M | — | -180.5M | — | — | — |
| Inv CF | -0.8M | -168.0M | 64.4M | -70.6M | 168.5M | — | — | — | — | — |
| Fin CF | 293.5M | 115.7M | 231.9M | 21.6M | 77.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NMRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NMRA | Neumora Therapeutics, Inc.(you) | $261M | 5 | Strong Sell |
| ALEC | Alector, Inc. | $261M | 5 | Strong Sell |
| LCTX | Lineage Cell Therapeutics, Inc. | $281M | 5 | Strong Sell |
| GLSI | Greenwich LifeSciences, Inc. | $230M | 4 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $260M | 10 | Strong Sell |
| AVXL | Anavex Life Sciences Corp. | $277M | 9 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $211M | 7 | Strong Sell |
| TARA | Protara Therapeutics, Inc. | $226M | 9 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%